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bjectives We sought to determine the best cardiac biomarker to predict infarct size, left ventricu-
ar ejection fraction (LVEF), and clinical outcome in patients undergoing primary percutaneous coro-
ary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
ackground The cardiac biomarkers, creatine kinase (CK), CK-MB, and troponins T and I are rou-
inely measured after myocardial infarction. However, their correlation with functional and clinical
utcomes after PCI for STEMI is not well established.
ethods In the EVOLVE (EValuation Of MCC-135 for Left VEntricular Salvage in Acute Myocardial
nfarction) trial, patients were randomized to receive intracellular calcium modulator as adjunct to
rimary PCI for ﬁrst large STEMI. Cardiac biomarker levels were determined in 378 patients before
CI and serially up to 72 h. Single-photon emission computed tomography was performed after 5
nd 30 days, and patients were monitored up to 180 days.
esults All single time-point, peak, and area under time-concentration curve of CK, CK-MB, and tro-
onins T and I after PCI signiﬁcantly correlated with infarct size and LVEF. In particular, 72-h tropo-
in I (TnI72h) correlated strongly with 5-day and 30-day infarct size (r  0.70; p  0.001). A TnI72h
hreshold 55 ng/ml was 90% sensitive for large infarct size (10%) and low LVEF (40%) with
peciﬁcities of 70% and 52%, respectively (c  0.88, 0.81; p  0.001). The highest TnI72h tertile was
ssociated with increased 180-day composite clinical events (23% vs. 23% vs. 42%; p  0.001) and
ndependently predicted adverse events (hazard ratio  2.3; p  0.01).
onclusions Assessing TnI72h after primary PCI is a simple, effective method to estimate infarct
ize, LVEF, and potentially useful for risk stratiﬁcation. (J Am Coll Cardiol Intv 2008;1:415–23)
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416easurement of cardiac biomarker levels is routinely per-
ormed in clinical practice, as well as in clinical trials after
yocardial infarction to estimate the extent of myocardial
ecrosis. Before the advent of thrombolytic therapy, venous
ampling of creatine kinase (CK) and CK-MB concentra-
ions provided a useful tool in estimating infarct size (1).
owever, with primary percutaneous coronary intervention
PCI) emerging as the preferred reperfusion modality for
cute ST-segment elevation myocardial infarction
STEMI) (2), it is less clear whether cardiac biomarker
elease still predicts infarct size, left ventricular (LV) func-
ion, and prognosis. Furthermore, with cardiospecific mark-
rs (i.e., troponin T and troponin I) gradually replacing
raditional cardiac enzymes in many practices (3), it is
uncertain which cardiac biomar-
ker or method (peak concentra-
t i on s , a r e a unde r t ime-
concentration curve [AUC], or
single time-point measure-
ments) is most reliable (4), con-
venient, and still demonstrates
strong correlation with infarct
size after primary PCI (5). Re-
cent studies suggested that a sin-
gle measurement of troponin T
72 to 96 h after myocardial in-
farction may provide an estimate
of infarct mass (6–8). Hence,
data validating the association of
cardiac biomarkers with infarct
size in a contemporary clinical
setting are clearly needed.
We, therefore, performed a
post hoc analysis of the database
from a prospective, multicenter,
randomized study of patients
with acute STEMI undergoing
primary PCI to evaluate the use-
fulness of serial and single time-
point measures of the cardiac
iomarkers CK, CK-MB, troponin T, and troponin I in
redicting infarct size and left ventricular ejection fraction
LVEF) determined by single-photon emission computed
omography (SPECT) imaging and clinical outcome.
ethods
tudy population. Details of the EVOLVE (EValuation Of
CC-135 for Left VEntricular Salvage in Acute Myocar-
ial Infarction) trial have been published previously (9,10).
n brief, the EVOLVE trial was a phase IIA, multicenter,
andomized, double-blind, placebo-controlled study of the
afety and efficacy of 2 doses of intravenous MCC-135, a
bbreviations
nd Acronyms
UC  area under time-
oncentration curve
I  confidence interval
K  creatine kinase
R  hazard ratio
V  left
entricle/ventricular
VEF  left ventricular
jection fraction
CI  percutaneous
oronary intervention
OC  receiver-operator
haracteristic
PECT  single-photon
mission computed
omography
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarction
nI72h  troponin I
oncentrations taken at 72 hew class of agent that reduces intracellular calcium over- goad, as an adjunct therapy for preservation of LV function
nd reduction of infarct size in patients undergoing PCI for
TEMI. A total of 500 patients were enrolled between May
003 and November 2004. Patients were included if they
ad a first documented STEMI and were to undergo
rimary PCI within 8 h of onset of symptoms. Principal
xclusion criteria were hemodynamic or electrical instability,
ardiogenic shock, severe bradycardia, pre-existing chronic
eart failure, renal impairment, or left bundle branch block
attern on electrocardiogram (ECG). All patients provided
itnessed informed consent, and the study was approved by
he ethics committees of all participating hospitals.
ardiac biomarker measurements. Protocol-specified blood
ampling for CK, CK-MB mass, troponin T, and troponin
was performed at baseline (before the start of study drug
nfusion and PCI) and 2, 4, 12, 24, 48, and 72 h thereafter
10 min for sampling window). All samples were analyzed
y a central core laboratory (Quest Diagnostics, Madison,
ew Jersey). Peak concentrations were identified, and AUC
as estimated from cardiac biomarker levels measured at
ndividual time-points. Troponin I concentrations taken at
2 h (TnI72h) were further stratified into tertiles to examine
or association with clinical characteristics and outcome.
roponin T was measured quantitatively using electro-
hemiluminescence technology (Elecsys Troponin T assay,
oche Diagnostics, Indianapolis, Indiana) with a detection
hreshold of 0.01 g/l. Troponin I was determined using a
icroparticle enzyme immunoassay (AxSym Troponin-I
DV, Abbott Laboratories, Abbott Park, Illinois) with an
nalytical sensitivity of 0.02 ng/ml and a diagnostic cutoff
or myocardial infarction of 0.40 ng/ml.
PECT and LV function assessments. Resting ECG-gated
yocardial SPECT imaging with Tc-99m-sestamibi or
c-99m-tetrofosmin was performed on Day 5 and when
atients returned for follow-up visit on Day 30 ( 2 days)
fter STEMI. In the study protocol, SPECT imaging was
nly performed in patients who underwent PCI and re-
eived study drug/placebo infusion. The acquisition of
CG-gated SPECT images was standardized in all clinical
ites and performed in concordance with standards of the
merican Society of Nuclear Cardiology (11). Infarct size,
VEF, and cardiac volumes were determined from the
econstructed SPECT images by core laboratory (Yale
niversity Radionuclide Core Laboratory, New Haven,
onnecticut) using Wackers-Liu CQ (WLCQ) software
GE Healthcare, Waukesha, Wisconsin) (12). Myocardial
erfusion defects (infarct size) were quantified and ex-
ressed as a percentage of the LV relative to a normal
eference database, and LVEF was determined using vali-
ated methodology (12,13).
ngiographic analysis. Standard image acquisition was per-
ormed at all clinical sites and submitted to an independent
ngiographic core laboratory for quantitative coronary an-
iography analyses.
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417linical outcomes. All patients were monitored during hos-
italization and thereafter by outpatient visits at 30 and 180
ays. Clinical outcome was the composite clinical end point
f death, reinfarction, new or worsening congestive heart
ailure during index hospitalization, or requiring rehospital-
zation, all cardiac rehospitalizations, life-threatening ven-
ricular arrhythmias, and new cardiogenic shock. All clinical
vents were adjudicated by an independent clinical events
ommittee.
tatistical analysis. Since there was no significant difference
n cardiac biomarker levels (including individual time-point,
eak, and AUC concentrations), infarct size, LVEF, and
linical outcome in the original study between patients
dministered with placebo or MCC-135 (10), all patients
ere merged into 1 cohort for statistical analyses in the
urrent protocol. Continuous variables were presented as
ean  SD. Biomarker levels over time were compared
ith baseline values using paired t test. Baseline character-
stics of patients with increasing TnI72h tertiles were
ompared using Kruskal-Wallis test, analysis of variance, or
hi-square test where appropriate. Correlation coefficients
eported were based on a nonparametric method (Spearman
ank). Related correlation coefficients were compared using
isher z-transformation. Time-to-event was defined as time
rom PCI to date of event, with patients censored at
re-specified clinical end points, loss to follow-up, or end of
tudy. Clinical outcomes were presented as Kaplan-Meier
urvival estimates and compared using log-rank test. A Cox
Table 1. Clinical Characteristics of the Overall Study Population and in Pat
Overall T
Number of patients, n 378
Clinical features
Age, yrs 58.9 11.9
Body mass index 28.0 4.9
Male gender, n (%) 289 (77)
Systolic blood pressure, mm Hg 132 21
Diastolic blood pressure, mm Hg 79 15
Heart rate, beats/min 75 15
Time from symptom onset to hospitalization, h 1.8 1.2
Killip class 1, n (%) 351 (93)
Anterior STEMI, n (%) 195 (52)
Cardiac risk factors, n (%)
Hypertension 177 (47)
Diabetes mellitus 68 (18)
Dyslipidemia 134 (35)
Previous coronary artery disease 37 (10)
Previous myocardial infarction 11 (3)
Peripheral artery disease 20 (5)
Family history myocardial infarction 125 (33)
Current smoker 171 (45)
Values are mean SD or n (%).STEMI ST-segment elevation myocardial infarction; TnI72h troponin I concentrations taken at 72 h.roportional hazards model was constructed to estimate
azard ratio and 95% confidence interval (CI) for elevated
nI72h that included age, gender, diabetes mellitus, hyper-
ension, tobacco use, left anterior descending artery as the
nfarct-related artery, Killip class, pre- and post-procedural
hrombolysis In Myocardial Infarction (TIMI) flow grades
nd corrected TIMI frame counts. Receiver-operator char-
cteristic (ROC) curves were generated using the dichoto-
ous variables infarct size 10% or 10% and LVEF 40
r 40% on Day 5. Statistical analysis was performed by
.C. and L.H. using Statistical Package for Social Sciences
5.0 software (SPSS Inc., Chicago, Illinois). All significance
ests were 2-sided, and the results were considered statisti-
ally significant when p  0.05.
esults
aseline demographics and angiographic features. Of the
00 patients enrolled, 378 (75.6%) patients who had under-
one primary PCI, SPECT imaging performed, and cardiac
iomarkers available for analysis form the study cohort of
his analysis. Clinical characteristics of the study population
nd procedural findings are shown in Tables 1 and 2.
All patients underwent primary PCI, and the left anterior
escending artery was identified as the culprit vessel in half
f the cohort (Table 2). Two-thirds of the patient popula-
ion had TIMI flow grade 0 or 1 in the culprit vessel at
aseline, and 85.7% had achieved TIMI flow grade 3 at the
Stratified by TnI72h
le 1
<39.5
Tertile 2
39.5 < TnI72h <96
Tertile 3
96 < TnI72h p Value
95 95
11.8 58.6 11.8 59.3 13.2 0.893
5.0 27.5 4.7 27.9 4.5 0.630
71) 73 (77) 73 (77) 0.543
21 132 21 132 22 0.945
15 80 14 82 15 0.010
13 75 16 77 16 0.069
1.1 1.7 1.2 1.9 1.4 0.240
93) 86 (91) 87 (92) 0.862
52) 48 (51) 59 (62) 0.219
43) 43 (45) 43 (45) 0.887
17) 19 (20) 19 (20) 0.793
42) 26 (27) 30 (32) 0.304
14) 10 (11) 6 (6) 0.299
2) 5 (5) 4 (4) 0.508
2) 6 (6) 7 (7) 0.294
33) 31 (33) 28 (30) 0.770
47) 47 (50) 39 (41) 0.491ients
Terti
nI72h
96
59.3
28.2
68 (
132
76
72
1.6
89 (
50 (
41 (
16 (
40 (
13 (
2 (
2 (
32 (
45 (
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418nd of the PCI procedure. Coronary stents were implanted
n 96% of cases with a mean of 1.2  0.6 stents implanted
er vessel.
atterns of cardiac biomarker release. Time-concentration
urves for the plasma levels of total CK, CK-MB, troponin
, and troponin I from time of enrollment to 72 h thereafter
re shown in Figure 1. The curves for CK, CK-MB, and
roponin I had monophasic profiles, reached peak levels by
to 12 h, and decreased steadily thereafter. Troponin T
elease appeared to reach a plateau and remained elevated at
2 h. Both total CK and CK-MB have reverted to or were
ower than initial levels by 72 h. Troponin T and troponin
, however, remained significantly elevated compared with
aseline levels (2.7  2.1 vs. 0.3  1.0 g/l, 83  80 vs. 16
54 ng/ml, respectively; both p  0.001).
orrelation between cardiac biomarkers, SPECT-determined
nfarct size, and LVEF. Individual time-point measurements
f plasma CK, CK-MB, troponin T, and troponin I
oncentrations as well as peak levels and AUC were posi-
ively correlated with SPECT-determined infarct size on
oth Day 5 and Day 30 (Table 3). A significant but more
oderate negative correlation between cardiac biomarkers
nd LVEF was also observed after primary PCI. The
orrelation coefficients between infarct size and cardiac
iomarkers at all time-points after PCI up to 72 h appeared
o be comparable. For the cardiac-specific markers, tro-
onins T and I, the strength of association was preserved
ven at later time-points. In particular, TnI72h showed a
trong correlation with infarct size determined both on Day
and Day 30 (r  0.70; p  0.001) and appeared to be
qually predictive compared with peak and AUC levels.
Table 2. Angiographic Characteristics of the Overall Study Population and
Overall
Terti
TnI72h
Baseline angiographic features
Infarct vessel  LAD, % 49.7 47
Reference vessel diameter, mm 2.99 0.51 2.96
Minimal luminal diameter, mm 0.24 0.32 0.35
Diameter stenosis, % 92.2 10.9 88.4
TIMI ﬂow grade 0 or 1, % 66.7 46
Corrected TIMI frame count 82.5 29.5 71.3
Procedural results
Patients with stents implanted, % 96 93
Number of stents in culprit vessel 1.2 0.6 1.2
Final minimal luminal diameter, mm 2.65 0.54 2.61
Final diameter stenosis, % 13.3 12.2 13.9
Final TIMI ﬂow grade 3, % 85.7 92
Final corrected TIMI frame count 27.3 18.3 23.9
Values are mean SD.
LAD left anterior descending artery; TIMI Thrombolysis In Myocardial Infarction; TnI72h trompared with troponin T measured at 72 h, TnI72h aemonstrated a trend for stronger correlation with infarct
ize (p  0.065).
Figure 2 shows the plotted correlations between single
ime-point measurement of TnI72h with infarct size (r 
.734, r2  0.539; p  0.001) and LVEF assessed on Day
(r  0.459, r2  0.211; p  0.001).
linical features and outcome of patients stratiﬁed by tertiles
f TnI72h. To further evaluate the implication of elevated
nI72h, patients were stratified into tertiles of TnI72h (n
86). Clinical and procedural characteristics of patients in
ach tertile are shown in Tables 1 and 2. There were no
ignificant differences in cardiac risk profile or time from
ymptom onset to hospitalization between the groups.
atients with higher TnI72h concentrations were more
ikely to have smaller minimal luminal diameter, higher
ercent diameter stenosis of the infarct artery, and reduced
nitial TIMI flow grades (0 or 1) than patients with lower
nI72h values. Rate of TIMI flow grade 3 was also lower in
he infarct artery post-procedure in patients with higher
nI72h levels, with a trend towards greater final corrected
IMI frame counts.
Composite and individual clinical end points stratified by
ertiles of TnI72h levels are presented in Figure 3 and Table
. At 180 days, the rates of composite clinical events were
reatest in patients with the highest TnI72h tertile level
23% vs. 23% vs. 42%; log-rank ptrend  0.001). Seven
atients in the study died, and they were all in the group
ith the highest TnI72h tertile. The association between
levated levels of TnI72h and combined clinical end point at
80 days was independent of other important clinical
redictors available at presentation, including age, gender,
iabetes, hypertension, tobacco use, left anterior descending
ients Stratified by TnI72h
Tertile 2
39.5 < TnI72h <96
Tertile 3
96 < TnI72h p Value
49.5 62.8 0.071
2.97 0.52 3.07 0.54 0.317
0.18 0.26 0.20 0.30 0.001
94.5 9.4 93.7 10.0 0.001
73.7 76.8 0.001
86.8 27.8 88.0 23.9 0.001
98 96 0.343
1.2 0.5 1.1 0.5 0.667
2.62 0.51 2.72 0.61 0.313
13.6 10.0 13.7 13.8 0.990
86.3 73.7 0.001
28.0 22.3 30.4 21.6 0.086
I concentrations taken at 72 h.in Pat
le 1
<39.5
.3
0.52
0.36
11.8
.9
33.9
0.8
0.53
11.9
.7
9.7rtery as the infarct-related artery, Killip class status, pre-
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419nd post-procedural TIMI flow grades, and corrected TIMI
rame counts (adjusted hazard ratio for highest TnI72h
ertile: 2.3, 95% CI: 1.2 to 4.2; p  0.01).
ccuracy of TnI72h in predicting large infarct size and low
VEF. The accuracy of TnI72h in predicting SPECT-
etermined infarct size and low LVEF on Day 5 was
xamined using ROC curve analyses. The AUC for predict-
ng large residual infarct size (10%) was 0.88 (95% CI:
.84 to 0.92; p  0.001), and for detecting LVEF 40%
as 0.81 (95% CI: 0.75 to 0.89; p 0.001). Conversely, the
UC for detecting very small residual defect size after 5
ays (5%) was 0.87 (95% CI: 0.82 to 0.91; p  0.001).
sing a threshold value of 55 ng/ml, TnI72h had 90%
ensitivity and 70% specificity in detecting large infarct size,
s well as 90% sensitivity and 52% specificity in predicting
ow LVEF. In contrast, a TnI72h value of 35 ng/ml had
0% sensitivity and 90% specificity for small or no residual
efect after PCI.
When the same analyses were applied to TnI72h, a cutoff
alue of 1.6 g/l was found to have 90% sensitivity of
redicting large residual infarct size (c 0.83, 95% CI: 0.78
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Figure 1. Time-Concentration Curves for Cardiac Biomarkers
Time-concentration curves for cardiac biomarkers (creatine kinase [CK]-MB, tot
cutaneous coronary intervention.o 0.88; p  0.001) and detecting LVEF 40% (c  0.77, L5% CI: 0.69 to 0.85; p  0.001) but poor specificities of
9% and 43%, respectively.
iscussion
e compared 4 established cardiac biomarkers (CK, CK-
B, troponin T, and troponin I) in estimating infarct size
nd LVEF in patients undergoing primary PCI for acute
TEMI. We found that single time-point assessment as
ell as AUC and peak levels of all 4 biomarkers were
ignificantly correlated with infarct size, while demonstrat-
ng a moderate inverse correlation with LVEF. In particu-
ar, a single measurement of TnI72h strongly correlated
ith infarct size and independently predicted cardiac out-
omes. Using a threshold value of 55 ng/ml, TnI72h had
0% sensitivity in predicting a large residual infarct (10%)
nd LV dysfunction (LVEF 40%) after primary PCI for
rst STEMI. We, therefore, concluded that troponin I
easured 72 h after primary PCI represented a simple,
ffective, and inexpensive tool determining infarct size and
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420Assessment of myocardial damage after STEMI is crucial
n evaluating the efficacy of reperfusion therapy and predict-
ng prognosis (14–16). Although measurements of LV
unction are often used clinically to estimate infarct size,
hey are less direct and are influenced by the presence of
rrhythmias, cardiomyopathies, valvular heart disease, and
entricular loading. In this present study, we used SPECT
maging to directly quantify infarct size, a robust and
linically validated method using a standardized approach.
Table 3. Correlation Analysis Between Cardiac Biomarkers (CK, CK-MB, Tr
and AUC With SPECT-Determined Infarct Size and LVEF
Cardiac Biomarkers Time, h n
Infarct S
r Value
Total CK Admission 307 0.229*
2 315 0.677*
4 322 0.708*
12 318 0.667*
24 331 0.599*
48 319 0.599*
72 264 0.554*
Peak 354 0.730*
AUC 348 0.669*
CK-MB Admission 363 0.251*
2 357 0.603*
4 358 0.634*
12 357 0.553*
24 367 0.516*
48 350 0.441*
72 292 0.478*
Peak 373 0.661*
AUC 369 0.634*
Troponin T Admission 258 0.139†
2 333 0.632*
4 342 0.633*
12 333 0.575*
24 352 0.664*
48 346 0.655*
72 277 0.653*
Peak 374 0.684*
AUC 367 0.702*
Troponin I Admission 347 0.254*
2 346 0.664*
4 348 0.687*
12 345 0.644*
24 359 0.701*
48 347 0.725*
72 282 0.734*
Peak 373 0.740*
AUC 369 0.748*
*p  0.001; †p  0.05.
AUC area under time-concentration curve; CK creatine kinase; LVEF left ventricular ejectiolthough the sensitivity of SPECT imaging for detection of umall subendocardial myonecrosis is lower than cardiac
agnetic resonance (17), it is reliable in patients with large
yocardial infarction, and also demonstrates comparability
hen acquired from different clinical centers (5). Neverthe-
ess, quantifying infarct size with both these noninvasive
maging modalities is limited by availability and relatively
igh costs. The cytosolic enzymes, CK, CK-MB, and
actate or hydroxybutyrate dehydrogenase, are frequently
sed as alternatives but lack cardio-specificity and cannot be
n T, and Troponin I) at Different Time-Points
ay 5
n
Day 30
LVEF
r Value
Infarct Size
r Value
LVEF
r Value
0.151* 255 0.183† 0.154†
0.388* 261 0.680* 0.545*
0.378* 269 0.707* 0.523*
0.379* 264 0.652* 0.495*
0.333* 275 0.576* 0.430*
0.311* 267 0.538* 0.394*
0.312* 214 0.532* 0.406*
0.381* 295 0.705* 0.488*
0.387* 291 0.661* 0.491*
0.163* 288 0.185* 0.143*
0.336* 283 0.606* 0.458*
0.349* 283 0.635* 0.452*
0.324* 282 0.557* 0.432*
0.307* 291 0.516* 0.389*
0.235* 278 0.419* 0.349*
0.294* 232 0.419* 0.329*
0.361* 295 0.646* 0.438*
0.360* 292 0.618* 0.456*
0.033 214 0.026 0.004
0.370* 269 0.603* 0.501*
0.369* 273 0.608* 0.456*
0.340* 266 0.562* 0.460*
0.344* 281 0.592* 0.426*
0.367* 275 0.628* 0.470*
0.426* 219 0.617* 0.514*
0.404* 295 0.631* 0.468*
0.394* 292 0.655* 0.496*
0.140† 275 0.204* 0.137†
0.357* 275 0.636* 0.474*
0.374* 275 0.675* 0.499*
0.398* 272 0.596* 0.506*
0.396* 285 0.649* 0.503*
0.419* 276 0.671* 0.529*
0.459* 223 0.711* 0.563*
0.434* 295 0.692* 0.518*
0.427* 292 0.691* 0.537*
on; SPECT single-photon emission computed tomography.oponi
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izenequivocally attributed to myocardial necrosis (18). In
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421ontrast, cardiac troponins have improved specificity and
hould be more precise in assessing infarct size (3).
In this study, we demonstrated significant correlation
etween SPECT-determined infarct size and peak and
UC cardiac biomarker levels. Clinical utility of these
erological estimates, however, is hampered by the require-
ent for serial and multiple measurements to avoid missing
ctual peak levels and complete profiles of the time-
oncentration curve. Moreover, obtaining true troponin
UCs is impractical since they remain elevated for up to 2
eeks. Hence, our main finding that TnI72h, measured at
single time-point of 72 h after PCI, was a reliable
ndicator of infarct size would be valuable in clinical
ractice. The kinetics of troponin I release are reperfusion-
Troponin I concentrations at 72 hr, ng/mL
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Figure 2. TnI72h Correlates With Infarct Size and LVEF
Correlation between troponin I levels taken at 72 h (TnI72h) after admis-
sion and single-photon emission computed tomography (SPECT)-deter-
mined myocardial infarct size and left ventricular ejection fraction (LVEF) on
Day 5.ependent, reaching an earlier maximal level and corre-ponding faster decline compared with that seen in nonre-
ascularized STEMI patients (19). In agreement with
revious studies, we showed that troponin I peak concen-
rations are attained between 4 to 12 h and remained mildly
levated 72 h after reperfusion (19,20). Three preliminary
mall studies recently showed that troponin T measured 72
nd 96 h after myocardial infarction indeed correlated well
ith infarct size determined by SPECT and contrast-
nhanced magnetic resonance imaging, respectively (6–8).
everal small studies have also sought to determine the
ignificance of troponin I in patients with myocardial
nfarction (20–23). However, to our knowledge, no clinical
rial has evaluated the direct association between troponin I
nd SPECT-determined infarct size after primary PCI in
large cohort nor made systematic comparisons with other
ardiac biomarkers.
Elevated TnI72h levels were associated with increased
isk of adverse clinical outcome after primary PCI in our
tudy population, driven largely by increased rates of mor-
ality and new or worsening congestive heart failure. The
verall mortality was low despite the attempt to enroll
atients with relatively large myocardial infarction, as we
xcluded those with cardiogenic shock or significant comor-
id conditions. Hence, we could only demonstrate adverse
rognosis in those with the highest TnI72h tertile and
argest infarct size, rather than a continuum of risk. The
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Figure 3. Cumulative Event-Free Survival Stratified by TnI72h
Kaplan-Meier estimates of survival free of composite clinical end points
among patients stratiﬁed by plasma troponin I concentrations taken at
72 h (TnI72h).
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422rognostic implication of elevated TnI72h may be attrib-
ted, in part, to greater frequency of suboptimal TIMI
cores post-procedure leading to larger residual infarct size
nd poorer LV function. We also assessed LV dysfunction,
 major determinant of long-term mortality and morbidity,
 month after PCI, which would more likely reflect irre-
ersible myocardial damage. Hence, TnI72h status may aid
n selection of patients at higher risk that require more
ntensive supervision and follow-up.
Using ROC curves, we further showed that TnI72h
as sensitive and specific for detecting large residual
nfarct size as well as impaired LV function. A cutoff
alue of TnI72h 55 ng/ml would predict 90% of
atients with large residual infarct in our population,
hile only 10% of patients with TnI72h value 35 ng/ml
ould have a residual defect larger than 5%. If troponin
 was measured in place of TnI72h, a corresponding
alue of 1.6 g/l would yield similar sensitivity that was
ess specific for large residual infarct size. Applying these
riteria to interpret TnI72h levels would be helpful in
stimating residual myocardial damage and LV function.
iven the affordability and routine availability of tropo-
in I assays, using TnI72h to assess myocardial defect or
VEF after primary PCI will be an attractive tool in both
linical practice and as potential surrogate end points in
linical trials.
tudy limitations. Our study has important limitations. It is
 hypothesis-generating post hoc analysis examining the
ssociation of cardiac biomarkers with infarct size. We do
ot believe that these data are sufficient to recommend
eplacement of more objective measures of LVEF or infarct
ize at present, but further prospective studies with myocar-
ial infarct imaging are warranted. The study was also not
owered to compare the strength of correlation between
ndividual time-points of cardiac biomarkers with infarct
ize. Nevertheless, our data provide sufficient support for
nI72h as an effective surrogate for infarct size that was
ore convenient compared with other measures. Our ob-
ervations were restricted to patients with relatively large
ocumented STEMI who underwent primary PCI within
 h of chest pain, and could not be generalized to those with
Table 4. Kaplan-Meier Estimates of the Cumulative Clinical Outcome at 18
180-Day Clinical Events (Cumulative)
Tertile 1
TnI72h <39.5 (n  96)
Composite clinical end point, % 23
Death, % 0
Reinfarction, % 1
Cardiogenic shock, % 1
Life-threatening ventricular rrhythmia, % 0
Congestive heart failure: new or worsened, % 6
Rehospitalization for cardiac cause, % 21lternative treatment strategies, delayed intervention, orho proceeded to surgery after diagnostic angiography, or if
ifferent troponin I assays were used. We also excluded
atients with prior myocardial infarction, multiple comorbid
onditions such as renal impairment and pre-existing con-
estive heart failure. Hence, the relationship between infarct
ize with biomarker release may be less robust in other
linical scenarios and may not apply to patients with
mall-size infarction or non-STEMI. Although overestima-
ion of infarct size may occur in patients with prior silent
nfarcts, this is unlikely as we carefully excluded those with
linical or electrocardiographic evidence of previous
TEMI. The cardiac biomarker levels were incomplete for
ertain time-points and may have implications if the miss-
ng data were significantly different from those reported.
ardiac biomarkers obtained after 72 h potentially may have
rovided a more optimal estimation of infarct size. How-
ver, the clinical utility of these assessments are diminished
n routine clinical practice as many patients are discharged 3
ays after primary PCI. The contribution of right ventric-
lar infarction to biomarker release could also confound the
orrelation analyses for LV function.
onclusions
 single assessment of TnI72h after primary PCI may be
sed to determine infarct size. Our data support the use of
his convenient measure in risk stratification in clinical
ractice.
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s Stratified by Plasma Troponin I Concentrations Taken at 72 h
Tertile 2
39.5 < TnI72h <96 (n  95)
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